New Tool: ProSource
Checkout our packaging and processing solutions finder, ProSource.

FDA Says Not to Buy Young Blood Transfusions

The FDA officially says there is no clinical evidence that young blood transfusions do anything, and the procedure could be dangerous.

Young Blood / Image: Cory Zapatka
Young Blood / Image: Cory Zapatka

We’ve all heard of the trend of transfusing blood from younger people to slow the process of aging, but does it actually work? According to a recent article from The Verge, the FDA says no, and it could actually be dangerous. The FDA released a statement officially warning consumers that buying young blood transfusions to improve their health is a bad idea:

“Simply put, we’re concerned that some patients are being preyed upon by unscrupulous actors touting treatments of plasma from young donors as cures and remedies. Such treatments have no proven clinical benefits for the uses for which these clinics are advertising them and are potentially harmful.”

A 2017 clinical trial found that young blood transfusions did almost nothing to treat Alzheimer. On top of that, the procedure leads to a few dozen deaths reported to the FDA each year. Worth the risk? I think not.

Test Your Supply Chain Smarts
Take Healthcare Packaging's supply chain quiz to prove your knowledge!
Read More
Test Your Supply Chain Smarts
Discover Our Content Hub
Access Healthcare Packaging's free educational content library!
Read More
Discover Our Content Hub